Difference between revisions of "Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)"
Jump to navigation
Jump to search
(Created page with "==Preliminary data== #'''VISION:''' Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour...") |
m (PeterYang moved page Lutetium-177-PSMA-617 to Lutetium Lu 177 vipivotide tetraxetan (Pluvicto): FDA approval) |
(No difference)
| |
Revision as of 21:00, 24 March 2022
Preliminary data
- VISION: Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16;385(12):1091-1103. Epub 2021 Jun 23. link to original article link to PMC article PubMed NCT03511664